?Approvals for clinical trials awaited?: Dr Debasish Gupta speaks to Organiser on plasma therapy to treat COVID-19 patients
December 12, 2025
  • Read Ecopy
  • Circulation
  • Advertise
  • Careers
  • About Us
  • Contact Us
Android AppiPhone AppArattai
Organiser
  • ‌
  • Bharat
    • Assam
    • Bihar
    • Chhattisgarh
    • Jharkhand
    • Maharashtra
    • View All States
  • World
    • Asia
    • Europe
    • North America
    • South America
    • Africa
    • Australia
  • Editorial
  • International
  • Opinion
  • RSS @ 100
  • More
    • Op Sindoor
    • Analysis
    • Sports
    • Defence
    • Politics
    • Business
    • Economy
    • Culture
    • Special Report
    • Sci & Tech
    • Entertainment
    • G20
    • Azadi Ka Amrit Mahotsav
    • Vocal4Local
    • Web Stories
    • Education
    • Employment
    • Books
    • Interviews
    • Travel
    • Law
    • Health
    • Obituary
  • Subscribe
    • Subscribe Print Edition
    • Subscribe Ecopy
    • Read Ecopy
  • ‌
  • Bharat
    • Assam
    • Bihar
    • Chhattisgarh
    • Jharkhand
    • Maharashtra
    • View All States
  • World
    • Asia
    • Europe
    • North America
    • South America
    • Africa
    • Australia
  • Editorial
  • International
  • Opinion
  • RSS @ 100
  • More
    • Op Sindoor
    • Analysis
    • Sports
    • Defence
    • Politics
    • Business
    • Economy
    • Culture
    • Special Report
    • Sci & Tech
    • Entertainment
    • G20
    • Azadi Ka Amrit Mahotsav
    • Vocal4Local
    • Web Stories
    • Education
    • Employment
    • Books
    • Interviews
    • Travel
    • Law
    • Health
    • Obituary
  • Subscribe
    • Subscribe Print Edition
    • Subscribe Ecopy
    • Read Ecopy
Organiser
  • Home
  • Bharat
  • World
  • Operation Sindoor
  • Editorial
  • Analysis
  • Opinion
  • Culture
  • Defence
  • International Edition
  • RSS @ 100
  • Magazine
  • Read Ecopy
Home Bharat

?Approvals for clinical trials awaited?: Dr Debasish Gupta speaks to Organiser on plasma therapy to treat COVID-19 patients

Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), the Department of Science and Technology, was the first institution to obtain a go-ahead for carrying out plasma therapy research in Bharat. The Indian Council for Medical Research (ICMR) gave approval to SCTIMST to treat COVID-19 patients with 'convalescent-plasma therapy?

Archive ManagerArchive Manager
Apr 18, 2020, 02:42 pm IST
in Bharat
Follow on Google News
FacebookTwitterWhatsAppTelegramEmail
a_1  H x W: 0 x
 
Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), the Department of Science and Technology, was the first institution to obtain a go-ahead for carrying out plasma therapy research in Bharat. The Indian Council for Medical Research (ICMR) gave approval to SCTIMST to treat COVID-19 patients with ‘convalescent-plasma therapy’. In this backdrop, Dr Debasish Gupta, Professor and Head, Transfusion Medicine, SCTIMST, speaks to Arun Lakshman. Excerpts:
 
What do you mean by Plasma treatment and how effective is this for COVID patients?
 
The rationale behind this Convalescent Plasma therapy is that the COVID-19 recovered patients have significant neutralising antibody titres which can help in the disappearance of viremia if transfused to severely affected COVID-19 patients. Studies have shown significant improvement in the clinical signs and symptoms and laboratory parameters after the use of convalescent plasma in these patients. There was an increase in the oxy-haemoglobin saturation, decreased C-reactive protein along with radiological examination showing the varying degree of resolution of lung lesions. This approach of transfusing convalescent plasma can serve as a promising life-saving therapy for severe COVID-19 patients.
 
Are there any hurdles do carrying out this treatment?
 
Since this plasma is not collected from a normal health voluntary blood donor but from a recently recovered COVID-19 patient, there is a need for getting Ethical clearance, approval from Drugs Controller General (India) and State Drug Authority, approval by ICMR for clinical trials and of course the support and approval from State Health department, before this clinical trial on collection and therapy of Convalescent plasma is initiated.
 
Is there a limit to the number of patients who can be treated using plasma from a single donor?
 
Normally a volume of 200 ml of Convalescent plasma with high titre of Neutralising antibodies to SARS-CoV-2 is sufficient for treating one patient. Occasionally, one more unit may be required in some patients. From one Plasma donor, we can collect plasma ranging from 400 ml. to 1000 ml. depending on their body weight, plasma volume, general health condition, good laboratory parameters. Based on the collected volume, this plasma units can be divided in to 2 -5 units of 200 ml. each. Accordingly, the number of patients will be benefitted by one donation.
 
Have you lined up any potential donors for plasma?
 
Potential donors can be recruited only after their quarantine period is completed post-full recovery from the disease and certified by their COVID Clinic.
 
Is there any criteria for receiving plasma or whether plasma transfusion can be effectively done in all stages of the disease?
 
There are exclusive criteria laid down for identifying the patients who need Plasma Therapy on a priority basis. These criteria have to be followed by any centre undertaking Convalescent Plasma Therapy. Rationale use of these plasma units has to be strictly followed.
ShareTweetSendShareSend
✮ Subscribe Organiser YouTube Channel. ✮
✮ Join Organiser's WhatsApp channel for Nationalist views beyond the news. ✮
Previous News

Love Jihad in the time of CoronaLockdown: Jihadis led by CPM goon abduct Kerala Christian girl under quarantine

Next News

A Manifesto for Post-Corona World Order (Part I): A New Paradigm for a New World

Related News

Tejas Mk A1 Light Combat Aircraft

Fake news on Tejas fighter jet deal: How anti-Bharat X accounts launched a coordinated attack on defence pride

RSS Sarsanghchalak Dr Mohan Bhagwat

‘RSS not a reactionary force’: Dr Mohan Bhagwat at ‘RSS 100 Years of Sangh Journey – New Horizons’ in Tiruchirappalli

SDPI thugs threaten to demolish 100+ yr old Aralumoodu Shivapuram Mahadeva Temple in Neyyattinkara

Hindu Hate Watch- A Weekly Tracker: Over 30 disturbing cases of grooming, conversion pressure, and communal crimes

Thiruparankundram Hill in Madurai | Justice G.R. Swaminathan of the Madras High Court | Letter by former Judges

56 former Judges back Justice Swaminathan, call INDIA Bloc’s impeachment push a threat to judicial independence

Kerala: Cochin Shipyard to build next-generation electric transverse tugs for Svitzer

Kerala: Cochin Shipyard to build next-generation electric transverse tugs for Svitzer to meet global fleet needs

Asian Development Bank

India to grow at 7.2 percent in 2025-26, says ADB in upgraded economic outlook

Load More

Comments

The comments posted here/below/in the given space are not on behalf of Organiser. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Latest News

Tejas Mk A1 Light Combat Aircraft

Fake news on Tejas fighter jet deal: How anti-Bharat X accounts launched a coordinated attack on defence pride

RSS Sarsanghchalak Dr Mohan Bhagwat

‘RSS not a reactionary force’: Dr Mohan Bhagwat at ‘RSS 100 Years of Sangh Journey – New Horizons’ in Tiruchirappalli

SDPI thugs threaten to demolish 100+ yr old Aralumoodu Shivapuram Mahadeva Temple in Neyyattinkara

Hindu Hate Watch- A Weekly Tracker: Over 30 disturbing cases of grooming, conversion pressure, and communal crimes

Thiruparankundram Hill in Madurai | Justice G.R. Swaminathan of the Madras High Court | Letter by former Judges

56 former Judges back Justice Swaminathan, call INDIA Bloc’s impeachment push a threat to judicial independence

Kerala: Cochin Shipyard to build next-generation electric transverse tugs for Svitzer

Kerala: Cochin Shipyard to build next-generation electric transverse tugs for Svitzer to meet global fleet needs

Asian Development Bank

India to grow at 7.2 percent in 2025-26, says ADB in upgraded economic outlook

Representative image

Madhya Pradesh declared ‘Naxal-free’ as last 2 active Maoists surrender in Balaghat

Uttarakhand: Bhowali Mosque allegedly encroaches 43 nali of government land; Role of forest dept & admin questioned

A representative image

National supercomputing mission deploys 37 systems; Total capacity reaches 40 petaflops in Bharat

Awami League rejected the national elections scheduled for February 2026(File Photo)

Awami League rejects Bangladesh elections scheduled by the ‘killer fascist Yunus clique’s illegal Election Commission’

Load More
  • Privacy
  • Terms
  • Cookie Policy
  • Refund and Cancellation
  • Delivery and Shipping

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies

  • Home
  • Search Organiser
  • Bharat
    • Assam
    • Bihar
    • Chhattisgarh
    • Jharkhand
    • Maharashtra
    • View All States
  • World
    • Asia
    • Africa
    • North America
    • South America
    • Europe
    • Australia
  • Editorial
  • Operation Sindoor
  • Opinion
  • Analysis
  • Defence
  • Culture
  • Sports
  • Business
  • RSS @ 100
  • Entertainment
  • More ..
    • Sci & Tech
    • Vocal4Local
    • Special Report
    • Education
    • Employment
    • Books
    • Interviews
    • Travel
    • Health
    • Politics
    • Law
    • Economy
    • Obituary
  • Subscribe Magazine
  • Read Ecopy
  • Advertise
  • Circulation
  • Careers
  • About Us
  • Contact Us
  • Policies & Terms
    • Privacy Policy
    • Cookie Policy
    • Refund and Cancellation
    • Terms of Use

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies